Join us on Saturday, August 22^nd from 9:00 AM to 2:20 PM central time (10:00 AM to 3:20 PM eastern time). Breakfast and lunch buffets sponsored by AON.

• 9:00 AM – 9:05 AM — Introduction (Dr Divers)
• 9:05 AM – 9:55 AM — Module 1: Chronic Lymphocytic Leukemia (Dr Awan)
• 9:55 AM – 10:45 AM — Module 2: Gastroesophageal Cancers (Dr Klempner)
• 10:45 AM – 11:00 AM — Morning Break
• 11:00 AM – 11:50 AM — Module 3: Ovarian and Endometrial Cancer (Dr Westin)
• 11:50 AM – 12:40 PM — Lunch
• 12:40 PM – 1:30 PM — Module 4: Diffuse Large B-Cell Lymphoma (Dr LaCasce)
• 1:30 PM – 2:20 PM — Module 5: Lung Cancer (Dr Liu)
• 2:20 PM — Meeting adjourns

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Chronic Lymphocytic Leukemia (CLL)
Upon completion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers (eg, del[17p], TP53 mutations, IGHV gene rearrangements) in chronic lymphocytic leukemia (CLL), and refine molecular testing algorithms for patients newly diagnosed with this disease. 
• Individualize the selection of systemic therapy for newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences. 
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents. 
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options. 
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line therapy for CLL to effectively inform patients about the risks and benefits of this novel treatment strategy.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data with this strategy for patients with newly diagnosed and relapsed/refractory (R/R) CLL. 
• Appraise clinical investigator best practices for various R/R CLL management scenarios, and leverage this information to facilitate improved therapeutic decision-making. 
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and as applicable, discuss clinical trial participation with eligible patients. 

Gastroesophageal Cancers
Upon completion of this activity, participants should be able to 

• Review published research findings with HER2-targeted therapies for patients with newly diagnosed and R/R advanced HER2-positive gastroesophageal cancers, and assess the current role of various agents and regimens. 
• Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms. 
• Evaluate the biological rationale for the use of claudin 18.2 (CLDN18.2)-directed monoclonal antibody therapy in combination with chemotherapy as first-line treatment for HER2-negative, CLDN18.2-positive gastric or GEJ cancer, and optimally deploy this approach in patient care. 
• Recognize available clinical research findings with immune checkpoint inhibitors as neoadjuvant, adjuvant or perioperative therapy for patients with resectable gastric, GEJ and esophageal cancers, and consider the current role of these approaches. 
• Review the rationale for, available data with and ongoing studies evaluating novel agents and strategies for gastroesophageal cancers in order to prepare for potential clinical availability or to enhance clinical trial participation. 

Ovarian and Endometrial Cancer
Upon completion of this activity, participants should be able to 

• Recognize the rationale for targeting folate receptor alpha (FRα) in ovarian cancer (OC), and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs). 
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the role of this novel therapeutic strategy. 
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and integrate this novel approach into current management algorithms. 
• Assess the incidence of cadherin-6 expression in OC, and understand available data with and the structural components and mechanism of action of novel ADCs directed at this target. 
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease. 
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing gynecologic cancers, and consider the role of various approaches in patient care. 
• Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed ADCs for patients with gynecologic cancers, and consider available and emerging research findings with and the clinical potential of these agents. 
• Describe the scientific justification for, published data with and current research studies of novel agents and strategies for OC and EC, and effectively prioritize clinical trial opportunities for eligible patients. 

Diffuse Large B-Cell Lymphoma (DLBCL)
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate. 
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies for newly diagnosed and R/R DLBCL, and consider the current and future role of this therapeutic strategy. 
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted ADCs for R/R DLBCL. 
• Evaluate available clinical trial findings and ongoing research studies with BTK inhibitors for DLBCL. 
• Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with DLBCL. 
• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for various forms of DLBCL, and assess the similarities and differences among currently available agents in this class. 
• Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for the management of R/R DLBCL, and optimally incorporate these approaches into current treatment algorithms. 
• Assess available research findings with CD19-directed bispecific antibodies for DLBCL, and consider the potential role of these agents in therapy for patients with this disease. 
• Recall new data with agents and strategies currently under investigation for DLBCL, and discuss ongoing trial opportunities with eligible patients. 

Lung Cancer
Upon completion of this activity, participants should be able to

• Appreciate the incidence of HER2 mutations and overexpression in metastatic non-small cell lung cancer (NSCLC), and recognize published clinical trial data with and the current role of novel ADCs for HER2-positive disease. 
• Review available clinical trial data evaluating the efficacy and safety of HER2-targeted tyrosine kinase inhibitors for patients with HER2-mutant NSCLC, and optimally identify individuals appropriate for this novel therapeutic strategy. 
• Convey the clinical relevance of a positive ROS1 mutation testing result to appropriate patients with NSCLC, and appreciate available clinical research findings with recently approved and emerging agents demonstrating efficacy for these individuals. 
• Appreciate the biological rationale for the evaluation of TROP2-directed ADCs for various lung cancer patient populations, and identify individuals appropriate for therapy with FDA-approved and investigational agents. 
• Understand the biology of EGFR exon 20 insertion mutations, and evaluate how currently available and emerging therapies can be employed in the care of patients with NSCLC harboring these abnormalities. 
• Reflect on investigational agents and strategies currently in testing for lung cancer in preparation for the potential clinical availability of these approaches. 

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 4.25 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statement
This educational activity for 4.25 contact hours is provided by Research To Practice.

This activity is awarded 4.25 ANCC pharmacotherapeutic contact hours.

ONCC/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/AON2026/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.0425 CEU (4.25 contact hours) of continuing education credit. To receive 4.25 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc. Dr Klempner — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EsoBiotec, Gilead Sciences Inc, I-Mab Biopharma, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Signet Therapeutics, Taiho Oncology Inc; Consulting Agreements: Astellas; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, I-Mab Biopharma, Mersana Therapeutics Inc, Parabilis Medicines; Data and Safety Monitoring Boards/Committees: Sanofi; Stock OPTIONS — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie’s Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation. Dr LaCasce — Advisory Committees: Caribou Biosciences Inc, Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Genmab US Inc, Pierre Fabre, Takeda Pharmaceuticals USA Inc. Dr Liu — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson, Merck, Merus, Natera, Novartis, Nuvalent, OSE Immunotherapeutics, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, SystImmune Inc, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Avenzo Therapeutics, BioNTech SE, Cogent Biosciences, Duality Biologics, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Henlius, MediLink Therapeutics, Merck, Merus, Nuvalent, Nuvation Bio Inc, OSE Immunotherapeutics, Puma Biotechnology Inc, Synthekine, SystImmune Inc. Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.

MODERATOR
Dr Divers — Advisory Committees: Daiichi Sankyo Inc.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP,  BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Genmab US Inc, Jazz Pharmaceuticals Inc, and Lilly.

JW Marriott Nashville
201 8th Avenue South
Nashville, TN 37203
Hotel Phone: (615) 291-8600

Meeting Room
Griffin A, B, C, D (second floor)

Hotel Room Reservations

• American Oncology Network (AON) members, please be sure to book accommodations in the AON room block.
• For all other registrants, room reservation information will be included in the confirmation email after you have registered for this program.

MODULES 1, 2 AND 3: Chronic Lymphocytic Leukemia, Gastroesophageal Cancers and Ovarian and Endometrial Cancers

• Slide Presentations (PDF)
• Slide Presentations (PPT)

MODULES 4 AND 5: Diffuse Large B-Cell Lymphoma and Lung Cancer

• Slide Presentations (PDF)
• Slide Presentations (PPT)

This event has passed.

Thank you for your interest in our CME/MOC, ACPE and NCPD program. At this time online registration for in-person attendance is closed for this event. 

Our onsite registration desk will be open at 8:30 AM central time on Saturday, August 22nd. If you are interested in attending, please visit our registration desk in the foyer of Griffin Ballroom A-D on the second floor of the JW Marriott Nashville hotel. Please note, seating is limited for this event, and we will do our best to accommodate onsite registrants on a first come, first served basis but prioritizing clinicians in practice. Onsite registration does not guarantee participation in meal services.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.